Table 1 Patient characteristics (N = 115)
Median age, years (range) | 65 (35 – 92) |
Median follow-up, months (range) | 18 (3 – 49) |
Sex (%) | Â |
   male | 58 (50) |
   female | 57 (50) |
ECOG performance status (%) | Â |
   0 | 31 (27) |
   1 | 71 (62) |
   2 | 8 (7) |
   3 | 1 (1) |
   Unknown | 4 (3) |
Weight loss before treatment (%) | Â |
   ≥ 10% | 24 (21) |
   < 10% | 91 (79) |
AJCC stage grouping (%) | Â |
   IA/IB | 22 (19) |
   IIA/IIB | 5 (4) |
   IIIA | 34 (30) |
   IIIB | 54 (47) |
Comorbidities (%) | Â |
   COPD | 30 (26) |
   Cardiovascular disease | 59 (52) |
   Smoker | 100 (87) |
Pathologic classification (%) | Â |
   Adenocarcinoma | 43 (37) |
   Squamous cell carcinoma | 39 (34) |
   Large cell carcinoma | 3 (3) |
   Mixed | 2 (2) |
   Non-small cell not otherwise specified | 28 (24) |
Grade (%) | Â |
   Well-differentiated | 7 (6) |
   Moderately differentiated | 12 (10) |
   Poorly differentiated | 55 (48) |
   No grade indicated | 41 (36) |
Location (%) | Â |
   Right | 63 (54) |
   Left | 49 (43) |
   Mediastinal nodal disease only | 3 (3) |
Staging workup (%) | Â |
   PET scan performed | 86 (75) |
   Mediastinoscopy performed | 16 (14) |
Chemotherapy (%) | Â |
   Induction | 55 (47) |
   Concurrent |  |
Taxane/platinum based | 62 (54) |
Other | 18 (16) |
Treated on clinical protocol (%) | 44 (38) |
Radiation treatment (%) | Â |
   Mean dose | 64 Gy |
   > 66 Gy | 8 (7) |
   > 63 – 66 Gy | 29 (25) |
   60 – 63 Gy | 75 (65) |
   < 60 Gy | 3 (3) |
   Mean treatment duration (days) | 45 |